- Leading Proxy Advisor Recommends Shareholders Support Merger
IRVINE, Calif., Sept. 19 /CNW/ -- IsoTis, Inc. (Nasdaq: ISOT) ("IsoTis"),
an orthobiologics company, today announced that Institutional Shareholder
Services, ISS, a leading proxy advisor, recommends shareholders support the
merger of IsoTis and Integra LifeSciences Holdings Corporation (Nasdaq: IART)
For every M&A analysis, ISS reviews publicly available information and
evaluates the merits and drawbacks of the proposed transaction, balancing
various and sometimes countervailing factors including valuation, market
reaction, strategic rationale, negotiations and process, conflicts of interest
and governance. Regarding the IsoTis-Integra combination, ISS cites the
following factors in particular:
"In reaching its decision to enter into the merger, the IsoTis board
evaluated, among other things, the following factors:
-- (i) the merger consideration of $7.25 per share represents an
approximately 5.4 percent premium over the closing price of the
company's common stock on August 6, 2007, the last trading day
prior to the announcement of the transaction;
-- (ii) the lack of any other viable financing or strategic alternatives
available to the company that would be expected to enhance
stockholder value, despite the company's extensive efforts to
pursue such alternatives since the withdrawal of the company's
initial public offering; and
-- (iii) the risks of remaining independent, including management's
assessment that if the company remains independent, it likely
will not be able to obtain financing and will run out of cash to
continue operations after October 2007, requiring the company to
consider seeking bankruptcy protection.
The company has been operating on a net income and cash flow deficit and
expects this to continue for the foreseeable future. Despite its efforts, the
company has been unable to obtain a viable financing alternative and believes
it will run out of cash to operate the business in October 2007. The company
believes that if the merger is not consummated, the company may be forced to
declare bankruptcy that will result in a decrease in the value of its common
The ISS report concludes, stating, "Based on our review of the terms of
the transaction and the factors described above, specifically the one-day
market premium and the company's financial condition, we believe that the
merger agreement warrants shareholder support."
In advance of the October 11, 2007 stockholder meeting, IsoTis intends to
hold information meetings for its European stockholders on the following
-- September 25, 2007, 6 p.m., local time, at Hotel Alpha-Palmiers,
located in Lausanne, Switzerland
-- September 26, 2007, 6 p.m., local time, at Hotel Baur au Lac, located
in Zurich, Switzerland
-- September 27, 2007, 6 p.m., local time, at World Trade Center Schiphol
Airport, located in Amsterdam, The Netherlands
The purpose of these meetings is to provide stockholders with an
opportunity to ask questions regarding the acquisition of IsoTis by Integra.
Stockholders will not be asked to vote on the transaction during these
information meetings. IsoTis stockholders will vote on the transaction at the
October 11, 2007 special meeting of stockholders to be held in Irvine,
California. Stockholders are reminded that not voting on the transaction
effectively constitutes a vote against the merger. The IsoTis board of
directors recommends that IsoTis stockholders approve the Agreement and Plan
IsoTis is an orthobiologics company that develops, manufactures and
markets proprietary products for the treatment of musculoskeletal diseases and
disorders. IsoTis' current orthobiologics products are bone graft substitutes
that promote the regeneration of bone and are used to repair natural, trauma-
related and surgically-created defects common in orthopedic procedures,
including spinal fusions. IsoTis' current commercial business is highlighted
by its Accell line of products, which the company believes represents the next
generation in bone graft substitution.
On August 7, 2007 Integra and IsoTis announced that they have reached a
definitive agreement to create a global orthobiologics leader. The combination
would create a comprehensive orthobiologics portfolio, one of the largest
sales organizations focused on orthobiologics in the US, and multiple cross-
selling opportunities. The transaction is subject to approval of IsoTis'
stockholders, as well as other closing conditions and approvals. Upon closing,
IsoTis will become a wholly-owned subsidiary of Integra and Integra will be
one of the largest companies in the world focused on advanced technology in
Certain statements in this press release are "forward-looking statements"
within the meaning of Section 21E of the Securities Exchange Act of 1934, as
amended, IsoTis' proposed acquisition by Integra. Words such as "strategy,"
"expects," "plans," "anticipates," "believes," "may," "will," "might,"
"could," "would," "continues," "estimates," "intends," "pursues," "projects,"
"goals," "targets" or the negative or other variations thereof and other words
of similar meaning are intended to identify such forward-looking statements.
One can also identify them by the fact that they do not relate strictly to
historical or current facts. Such statements are based on the current
expectations and projections of the management of IsoTis only. Undue reliance
should not be placed on these statements because, by their nature, they are
subject to known and unknown risks and can be affected by factors that are
beyond the control of IsoTis. Actual results could differ materially from
current expectations and projections. Any forward-looking statements are made
pursuant to the Private Securities Litigation Reform Act of 1995 and, as such,
speak only as of the date made. IsoTis undertakes no obligation to publicly
update any forward-looking statements, whether as a result of new information,
future events or otherwise.
Important Information for Investors and Stockholders
IsoTis has filed a definitive proxy statement and other relevant
materials with the SEC in connection with the proposed merger with Integra.
IsoTis urges IsoTis stockholders to read the proxy statement and any other
relevant documents filed by IsoTis with the SEC because they will contain
important information. Investors and stockholders may obtain the proxy
statement and other documents filed with the SEC free of charge at the website
maintained by the SEC at http://www.sec.gov/. Documents filed with the SEC by
IsoTis are also available free of charge on the investor relations portion of
the IsoTis website at http://www.IsoTis.com/. The proxy statement was first
mailed to stockholders on or about September 5, 2007.
Participants in the Solicitation
IsoTis, and its directors and executive officers may be deemed to be
participants in the solicitation of proxies from IsoTis' stockholders in
connection with the proposed merger with Integra. The names of IsoTis'
directors and executive officers and a description of their interests in
IsoTis are set forth in IsoTis S.A.'s Annual Report on Form 20-F, which was
filed with the SEC on May 11, 2007. Investors and stockholders can obtain more
detailed information regarding the direct and indirect interests of IsoTis'
directors and executive officers in the merger by reading the definitive proxy
For further information:
For further information: Rob Morocco, CFO, +1-949-855-7155,
firstname.lastname@example.org; Hans Herklots, Director IR, +1-949-855-7195 or
+41-21-620-6011, email@example.com, both for IsoTis, Inc. Web Site: